Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma

Allovectin (velimogene aliplasmid) is a cancer immunotherapeutic currently completing a pivotal phase 3 study for metastatic melanoma. Consisting of a bicistronic plasmid encoding both major histocompatibility complex (MHC) class I heavy and light chains (HLA-B7 and β2-microglobulin, respectively) f...

Descripción completa

Detalles Bibliográficos
Autores principales: Doukas, J, Rolland, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499708/
https://www.ncbi.nlm.nih.gov/pubmed/23037806
http://dx.doi.org/10.1038/cgt.2012.69

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499708/
https://www.ncbi.nlm.nih.gov/pubmed/23037806
http://dx.doi.org/10.1038/cgt.2012.69

Ejemplares similares